D07.0
Carcinoma in situ of endometrium
Clinical Classification Guidelines
Medical Intelligence & Overview
Carcinoma in situ (CIS) of the endometrium is a condition characterized by abnormal, potentially precancerous cells confined to the inner lining of the uterus. Also known as endometrial intraepithelial neoplasia, it is considered a precancerous state that has not yet invaded deeper tissues. Recognizing and understanding this condition is essential for appropriate management and treatment planning, as it can develop into invasive endometrial cancer if left untreated.
Causes & Symptoms
Clinical Causes: Hormonal imbalances, especially excess estrogen without progesterone balance Obesity, which increases estrogen production Chronic anovulation, commonly seen in women with irregular or absent menstrual periods Use of hormone replacement therapy containing estrogen alone Certain genetic predispositions or familial cancer syndromes History of previous uterine conditions or endometrial hyperplasia
Key Symptoms: Abnormal uterine bleeding, such as bleeding between periods or postmenopausal bleeding Pelvic discomfort or pressure Unexplained weight changes or fatigue in advanced cases No symptoms in early stages, making detection often incidental during routine examinations or biopsies
Diagnostic & Treatment
Diagnosis Path: Diagnosis of carcinoma in situ of the endometrium typically involves a combination of clinical evaluation and laboratory procedures, including: - **Pelvic examination** to assess abnormalities in the uterus - **Endometrial sampling or biopsy**, which involves collecting cells from the lining of the uterus for examination under a microscope - **Transvaginal ultrasound** to visualize the endometrial thickness and structure - **Hysteroscopy**, a procedure that allows direct visualization of the uterine cavity and targeted biopsies - **Histopathological analysis** confirming the presence of atypical cells confined to the endometrial lining without invasion into deeper tissues
Treatment Protocols: The primary goal in managing carcinoma in situ of the endometrium is to remove or eradicate the abnormal cells to prevent progression to invasive cancer. Treatment options may include: - **Hormonal Therapy**: Use of progestins to reverse atypical proliferation and restore normal endometrial tissue - **Surgical Management**: Depending on patient age, reproductive desires, and extent of the lesion, procedures such as hysterectomy (removal of the uterus) may be recommended - **Close Monitoring**: Regular follow-up with endometrial sampling to assess treatment response and detect any recurrence - **Lifestyle Modifications**: Weight management and control of hormonal factors to reduce risk factors Early detection and appropriate intervention are critical for favorable outcomes in cases of carcinoma in situ of the endometrium.
Clinical Advice & FAQs
Billing Guidance
Is D07.0 a billable ICD-10 code?
Yes, D07.0 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D07.0?
Clinical documentation must specify the nature of Carcinoma in situ of endometrium and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
